Rokumi-jio-gan-containing prescriptions attenuate oxidative stress, inflammation, and apoptosis in the remnant kidney

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Park, Chan Hum ^a,b   Lee, Sul Lim ^a   Okamoto, Takuya ^a   Tanaka, Takashi ^c   Yokozawa, Takako ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Iskra Industry Co Ltd   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BAKUMIJIOGAN; CASPASE 3; CREATININE; CYCLOOXYGENASE 2; CYTOCHROME C; HACHIMIJIOGAN; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PLANT MEDICINAL PRODUCT; PROTEIN BAX; PROTEIN C JUN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN; TRANSCRIPTION FACTOR NF E2; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERIOLOSCLEROSIS; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DOWN REGULATION; FLUID INTAKE; FOOD INTAKE; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PARENCHYMA; MALE; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; UPREGULATION; UREA NITROGEN BLOOD LEVEL; WEIGHT CHANGE;

EID: 84871380991     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2012/587902     Document Type: Article

References (52)

1. Mitch W. E., Walser M., Brenner B. M., Rector F. C., Nutritional therapy of the uremic patient. The Kidney 1986 Philadelphia, USA Saunders 1756 1790
2. Kumano K., Takara S., Izumi H., The modification of dietary protein and administration of oral adsorbent AST-120 in chronic renal failure rats. Japanese Journal of Nephrology 1987 29 2 185 194 2-s2.0-0023113076 (Pubitemid 17045099)
3. Miyazaki M., Aoyagi K., Tojo S., Lactulose therapy for chronic renal failure. Japanese Journal of Nephrology 1984 26 8 1091 1098 2-s2.0-0021179132 (Pubitemid 14005622)
4. Ha H., Lee J. K., Lee H. Y., Koh W. S., Seo C. S., Lee M. Y., Huang D. S., Shin H., Safety evaluation of Yukmijihwang-tang: assessment of acute and subchronic toxicity in rats. Evidence-Based Complementary and Alternative Medicine 2011 2011 8 2-s2.0-79952129161 10.1155/2011/672136 672136
5. Huang T., Hachimi-jio-gan. A Handbook of Traditional Chinese Prescriptions of Dubious and Complicated Cases 1997 Beijing, China China Medical and Pharmaceutical Science and Technology Publishing House 527 538
6. Yamada T., Hachimi-jio-gan. Kinki Youryaku 1992 Tokyo, Japan Kyouwa-Kikaku 1 7
7. Yokozawa T., Yamabe N., Cho E. J., Nakagawa T., Oowada S., A study on the effects to diabetic nephropathy of Hachimi-jio-gan in rats. Nephron Experimental Nephrology 2004 97 2 e38 e48 2-s2.0-2942750122 10.1159/000078405
8. Nakagawa T., Yokozawa T., Yamabe N., Rhyn D. Y., Goto H., Shimada Y., Shibahara N., Long-term treatment with Hachimi-jio-gan attenuates kidney damage in spontaneously diabetic WBN/Kob rats. Journal of Pharmacy and Pharmacology 2005 57 9 1205 1212 2-s2.0-25844457347 10.1211/jpp.57.9.0016 (Pubitemid 41391780)
9. Yamabe N., Yokozawa T., Activity of the Chinese prescription Hachimi-jio-gan against renal damage in the Otsuka Long-Evans Tokushima Fatty rat: a model of human type 2 diabetes mellitus. Journal of Pharmacy and Pharmacology 2006 58 4 535 545 2-s2.0-33645580675 10.1211/jpp.58.4.0014
10. Yamabe N., Yokozawa T., Protective effect of Hachimi-jio-gan against the development of pancreatic fibrosis and oxidative damage in Otsuka Long-Evans Tokushima Fatty rats. Journal of Ethnopharmacology 2007 113 1 91 99 2-s2.0-34447546727 10.1016/j.jep.2007.05.010 (Pubitemid 47077853)
11. Sakagishi Y., Saito M., Kitamura M., Niwa M., Total protein. Rinsho Kagaku Bunseki II 1968 Tokyo, Japan Tokyo Kagaku Dojin 115 142
12. Ali S. F., LeBel C. P., Bondy S. C., Reactive oxygen species formation as a biomarker of methylmercury and trimethyltin neurotoxicity. Neurotoxicology 1992 13 3 637 648 2-s2.0-0026483404
13. Komatsu S., Extraction of nuclear proteins. Methods in Molecular Biology 2007 355 73 77 2-s2.0-39049190420
14. Himmelfarb J., Stenvinkel P., Ikizler T. A., Hakim R. M., The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney International 2002 62 5 1524 1538 2-s2.0-0036833743 10.1046/j.1523-1755.2002.00600.x (Pubitemid 35286260)
15. Vaziri N. D., Oxidative stress in uremia: nature, mechanisms, and potential consequences. Seminars in Nephrology 2004 24 5 469 473 2-s2.0-5444257487 10.1016/j.semnephrol.2004.06.026 (Pubitemid 39361056)
16. 1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. Journal of Pharmacology and Experimental Therapeutics 2007 323 1 85 93 2-s2.0-34548813412 10.1124/jpet.107.123638 (Pubitemid 47443257)
17. Kim H. J., Vaziri N. D., Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. American Journal of Physiology 2010 298 3 F662 F671 2-s2.0-77649093421 10.1152/ajprenal.00421.2009
18. Bedard K., Krause K. H., The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiological Reviews 2007 87 1 245 313 2-s2.0-33846794822 10.1152/physrev.00044.2005 (Pubitemid 46209993)
19. Griendling K. K., Sorescu D., Ushio-Fukai M., NAD(P)H oxidase: role in cardiovascular biology and disease. Circulation Research 2000 86 5 494 501 2-s2.0-0034677947 (Pubitemid 30165039)
20. Zalba G., José G. S., Moreno M. U., Fortuño M. A., Fortuño A., Beaumont F. J., Díez J., Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 2001 38 6 1395 1399 2-s2.0-0035678477 (Pubitemid 34033422)
21. Babior B. M., Lambeth J. D., Nauseef W., The neutrophil NADPH oxidase. Archives of Biochemistry and Biophysics 2002 397 2 342 344 2-s2.0-0037082101 10.1006/abbi.2001.2642 (Pubitemid 34852301)
22. phox in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia 2003 46 10 1428 1437 2-s2.0-0042864155 10.1007/s00125-003-1205-6 (Pubitemid 37297214)
23. phox are dominant inhibitors of Nox1- and Nox2-dependent reactive oxygen generation. Journal of Biological Chemistry 2005 280 36 31859 31869 2-s2.0-24744468043 10.1074/jbc.M501882200 (Pubitemid 41291936)
24. phox and Nox4 expression. Molecular Pharmacology 2006 70 3 897 908 2-s2.0-33747592582 10.1124/mol.106.023937 (Pubitemid 44268447)
25. Tong K. I., Katoh Y., Kusunoki H., Itoh K., Tanaka T., Yamamoto M., Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Molecular and Cellular Biology 2006 26 8 2887 2900 2-s2.0-33344463325 10.1128/MCB.26.8.2887-2900.2006
26. Kensler T. W., Wakabayashi N., Biswal S., Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annual Review of Pharmacology and Toxicology 2007 47 89 116 2-s2.0-33847050801 10.1146/annurev.pharmtox.46.120604.141046
27. Harvey C. J., Thimmulappa R. K., Singh A., Blake D. J., Ling G., Wakabayashi N., Fujii J., Myers A., Biswal S., Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress. Free Radical Biology & Medicine 2009 46 4 443 453 2-s2.0-58649100237 10.1016/j.freeradbiomed.2008.10.040
28. Li W., Kong A. N., Molecular mechanisms of Nrf2-mediated antioxidant response. Molecular Carcinogenesis 2009 48 2 91 104 2-s2.0-59849113546 10.1002/mc.20465
29. Anwar A. A., Li F. Y. L., Leake D. S., Ishii T., Mann G. E., Siow R. C. M., Induction of heme oxygenase 1 by moderately oxidized low-density lipoproteins in human vascular smooth muscle cells: role of mitogen-activated protein kinases and Nrf2. Free Radical Biology & Medicine 2005 39 2 227 236 2-s2.0-20444456655 10.1016/j.freeradbiomed.2005.03.012 (Pubitemid 40814548)
30. He M., Siow R. C. M., Sugden D., Gao L., Cheng X., Mann G. E., Induction of HO-1 and redox signaling in endothelial cells by advanced glycation end products: a role for Nrf2 in vascular protection in diabetes. Nutrition, Metabolism and Cardiovascular Diseases 2011 21 4 277 285 2-s2.0-79952700675 10.1016/j.numecd.2009.12.008
31. 2-terminal kinase activation via a glutathione reductase-mediated mechanism. Circulation Research 2002 91 8 712 718 2-s2.0-0037131208 10.1161/01.RES.0000037981.97541.25 (Pubitemid 35204954)
32. Kallunki T., Deng T., Hibi M., Karin M., c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 1996 87 5 929 939 2-s2.0-0030606319 10.1016/S0092-8674(00)81999-6 (Pubitemid 26404291)
33. Gupta S., Campbell D., Derijard B., Davis R. J., Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995 267 5196 389 393 2-s2.0-0028905076
34. Hocevar B. A., Brown T. L., Howe P. H., TGF- β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. The EMBO Journal 1999 18 5 1345 1356 2-s2.0-0033104505 (Pubitemid 29110318)
35. Baeuerle P. A., Henkel T., Function and activation of NF- B in the immune system. Annual Review of Immunology 1994 12 141 179 2-s2.0-0028174061
36. Viedt C., Hänsch G. M., Brandes R. P., Kübler W., Kreuzer J., The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF- B and AP-1. The FASEB Journal 2000 14 15 2370 2372 2-s2.0-0034571564
37. Surh Y. J., Chun K. S., Cha H. H., Han S. S., Keum Y. S., Park K. K., Lee S. S., Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF- B activation. Mutation Research 2001 480-481 243 268 2-s2.0-0035451363 (Pubitemid 32744832)
38. Chow F., Ozols E., Nikolic-Paterson D. J., Atkins R. C., Tesch G. H., Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney International 2004 65 1 116 128 2-s2.0-0346101486 10.1111/j.1523-1755.2004.00367.x (Pubitemid 38037496)
39. Kosugi T., Nakayama T., Heinig M., Zhang L., Yuzawa Y., Sanchez-Lozada L. G., Roncal C., Johnson R. J., Nakagawa T., Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. American Journal of Physiology 2009 297 2 F481 F488 2-s2.0-68049101366 10.1152/ajprenal.00092.2009
40. Sachse A., Wolf G., Angiotensin II-induced reactive oxygen species and the kidney. Journal of the American Society of Nephrology 2007 18 9 2439 2446 2-s2.0-34548496478 10.1681/ASN.2007020149 (Pubitemid 47378859)
41. Allen D. A., Harwood S., Varagunam M., Raftery M. J., Yaqoob M. M., High glucose-induced oxidative stress causes apoptosis in proximal tubular epithelial cells and is mediated by multiple caspases. The FASEB Journal 2003 17 8 908 910 2-s2.0-0037984766
42. Kang B. P. S., Frencher S., Reddy V., Kessler A., Malhotra A., Meggs L. G., High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism. American Journal of Physiology 2003 284 3 F455 F466 2-s2.0-0037369416 (Pubitemid 36227906)
43. Brezniceanu M. L., Liu F., Wei C. C., Chénier I., Godin N., Zhang S. L., Filep J. G., Ingelfinger J. R., Chan J. S. D., Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells. Diabetes 2008 57 2 451 459 2-s2.0-40749161602 10.2337/db07-0013
44. Crompton M., Bax, Bid and the permeabilization of the mitochondrial outer membrane in apoptosis. Current Opinion in Cell Biology 2000 12 4 414 419 2-s2.0-0033936787 10.1016/S0955-0674(00)00110-1 (Pubitemid 30453590)
45. Kashihara N., Sugiyama H., Makino H., Implication of apoptosis in progression of renal diseases. Contributions to Nephrology 2003 139 156 172 2-s2.0-0141922638
46. Wagener F. A. D. T. G., Dekker D., Berden J. H., Scharstuhl A., van der Vlag J., The role of reactive oxygen species in apoptosis of the diabetic kidney. Apoptosis 2009 14 12 1451 1458 2-s2.0-70449122033 10.1007/s10495-009- 0359-1
47. Remuzzi G., Ruggenenti P., Benigni A., Understanding the nature of renal disease progression. Kidney International 1997 51 1 2 15 2-s2.0-0031042356 (Pubitemid 27064516)
48. Remuzzi G., Bertani T., Pathophysiology of progressive nephropathies. New England Journal of Medicine 1998 339 20 1448 1456 2-s2.0-0032512094 10.1056/NEJM199811123392007 (Pubitemid 28516069)
49. Brenner B. M., Meyer T. W., Hostetter T. H., Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. New England Journal of Medicine 1982 307 11 652 659 2-s2.0-0020324688 (Pubitemid 12049914)
50. Bro S., Bentzon J. F., Falk E., Andersen C. B., Olgaard K., Nielsen L. B., Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. Journal of the American Society of Nephrology 2003 14 10 2466 2474 2-s2.0-0141455349 10.1097/01.ASN.0000088024.72216.2E (Pubitemid 37169332)
51. Sakai T., Kumano K., Takara S., Kuwao S., Ise M., Sugano M., Uehara Y., Effect of oral-adsorbent (AST-120) to chronic renal failure (CRF) in rats. Japanese Journal of Nephrology 1989 31 4 359 365 2-s2.0-0024543753 (Pubitemid 19116850)
52. Porkert M., Porkert M., Standards of value for phenomena of microcosmic dimensions I: orbisiconography. The Theoretical Foundations of Chinese Medicine 1978 Cambridge, UK The MIT Press 107 196